Jnj competitors.

The average twelve-month price prediction for Johnson & Johnson is $169.19 with a high price target of $215.00 and a low price target of $52.00. Learn more on JNJ's analyst rating history. Do Wall Street analysts like Johnson & Johnson more than its competitors?

Jnj competitors. Things To Know About Jnj competitors.

Johnson & Johnson is a comprehensive and broadly based manufacturer and provider of health care products and related services for consumer, pharmaceutical, medical devices, and diagnostics markets. Johnson & Johnson embraces research and science, bringing innovativ e ideas, products, and services to advance the health and well-being of people.And this unwavering commitment hasn’t gone unnoticed: Fortune just ranked Johnson & Johnson as a Top 50 All-Star on its World’s Most Admired Companies list for the 20th consecutive year. For 2022, the company ranked #1 on the Pharmaceutical Industry list for the ninth year in a row and in the top 20 on the overall Top 50 All-Stars list.Johnson & Johnson (NYSE:JNJ) EV/FCFF ratio. See how EV/FCFF has changed over time and compare its current value with the distribution of EV/FCFF across competitors.Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Eli Lilly and Company pays an annual dividend of $4.52 per share and has a dividend yield of 0.8%. Johnson & Johnson pays out 35.3% of its earnings in the form of a dividend.Cash flow Statement(Annual, GAAP in millions $) (Jan 01 2023) 12 Months. (Jan 02 2022) 12 Months. (Jan 03 2021) 12 Months. (Dec 29 2019) 12 Months.

Johnson & Johnson Company is a Pharmaceutical company all over the world. It was found in 1886 by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson. The company produced its first products in 1886 and incorporated in 1887. It became a public company in 1944, listed shares on the New York Stock Exchange with …

May 26, 2011 · A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Sep 25, 2013 ... Most investors recognize Johnson & Johnson (JNJ 2.40%) as a consumer ... competitors -- Boston Scientific (BSX 0.45%), Medtronic (MDT 0.91 ...

Apr 29, 2023 · The Business Model Canvas of Johnson & Johnson encompasses key elements such as customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure. Some of the competitors of Johnson & Johnson include Pfizer, Merck & Co., Novartis, and Gilead Sciences. Johnson And Johnson's Current Key Valuation Ratios, PE, PB, PCF, PS, compare to Major Pharmaceutical Preparations Industry and Healthcare SectorTools Learn Johnson & Johnson (JNJ) Alerts Watch Help Go To: Other Sectors containing Johnson & Johnson (JNJ) screen flipcharts download Competitors Competitors The Competitors page allows you to view information for other symbols found in the same sector.Johnson & Johnson main competitors are AbbVie, Bristol-Myers Squibb, and Eli Lilly and Company. Competitor Summary. See how Johnson & Johnson compares to its main competitors: Merck has the most employees (74,000). Employees at AbbVie earn more than most of the competitors, with an average yearly salary of $107,969.J&J Says They Made a Deal with ARC in 1895 (Score: 5, Informative) Johnson & Johnson on Wednesday sued the American Red Cross over the use by the relief group and its partners of J&J's trademark red cross logo on first aid kits, hand sanitizer and medical gloves sold to the public.

Aug 31, 2023 · Founded in 1886 in New Brunswick, New Jersey, Johnson & Johnson is one of the largest pharmaceutical, medical device, and consumer packaged goods manufacturers in the world. In 2022, the company ...

Overview Competitors Acquisitions Investments News & Insights Chairman & CEO …

Johnson & Johnson's main competitors include Unilever, Abbott, GSK, Medtronic, Novartis, Pfizer, Procter & Gamble, Roche and Bayer. Compare Johnson & Johnson to its competitors by revenue, employee growth and other metrics at Craft. View All Zacks #1 Ranked Stocks Johnson & Johnson (JNJ) Quote Overview » More Research » Johnson & Johnson (JNJ) Comparison to Industry Industry / Sector Report Enter Symbol Industry :...JNJ Competitors | Johnson & Johnson Common Stock Stock - Yahoo! Finance. N.p., n.d. Web. 08 Dec. 2013. . Read More. Proctor And Gamble Scope Case Analysis 1672 Words | 4 Pages. Each division has its own brand management, sales, finance, product development and operations line management and was evaluated as a …Johnson & Johnson's main competitors include Unilever, Abbott, GSK, Medtronic, …Johnson And Johnson detailed Quarterly and Annual EPS from Cont. Operations year on year Growth Analysis, results, statistics, averages, rankings and trends

Competition is fierce, certainly, with private label adoption one obvious concern. (In pain relief, for instance, the total global market share of private label competitors is more than 1.5x that ...April 19, 2022. New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson ’s 144,000 employees for their relentless passion ...Dec 1, 2023 · Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Eli Lilly and Company pays an annual dividend of $4.52 per share and has a dividend yield of 0.8%. Johnson & Johnson pays out 35.3% of its earnings in the form of a dividend. Johnson & Johnson (JNJ 1.68%) is a well-known consumer and healthcare company that has been in operation for more than a century. Meanwhile, Intuitive Surgical ( ISRG 0.03% ) has made a name for ...About Johnson & Johnson. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life.Commenting Third Quarter 2023 EBITDA Margin: Johnson and Johnson experienced contraction in EBITDA by -19.95 % to $ 21,351 millions and Revenue by -16.37 %, while EBITDA Margin fell to 33.9 %, above company's average EBITDA Margin. Observing third quarter 2023 results within Major Pharmaceutical Preparations industry 32 other …

www.jnj.com: Cheif Executive Officer: Alex Gorsky: Annual Sales Volume (2013) 71.3 Billion: Total Number of Employees: 128,100: Primary SIC Code: 2834 (Pharmaceutical Preparations) Primary NAICS Code: ... Competitors will follow Johnson and Johnson into the natural remedy options .Jun 23, 2020 ... Johnson & Johnson exits fairness cream market, but what about competitors? ... Though Johnson & Johnson (J&J), the US healthcare and FMCG giant ...

Johnson & Johnson's worldwide business is divided into three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a broad range of products used in the baby and child care, skin care, oral and wound care and women's health care fields, as well as nutritional and over-the-counter ... May 26, 2021 · JNJ and its competitors clearly demonstrate strong operating profits. This goes to show that even though the Pharma industry is highly competitive and revenue growth has been generally slow, the ... This time around we want to offer more social dancing than ever before, 6 open & intermediate level workshops, and a super fun and friendly JnJ competition (with prizes!!!) Back by popular demand we are happy to invite our Calgary teachers Tony and Esther and our Seattle/Toronto based couple Sian and Viet, as well as our own Vancouver based …JNJ Sales vs. its Competitors Q3 2023. Comparing the current results to its competitors, Johnson And Johnson reported Revenue decrease in the 3 quarter 2023 year on year by -10.26 %, despite the revenue increase by most of its competitors of 4.83 %, recorded in the same quarter. • List of JNJ Competitors. Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia …Dec 1, 2023 · Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Eli Lilly and Company pays an annual dividend of $4.52 per share and has a dividend yield of 0.8%. Johnson & Johnson pays out 35.3% of its earnings in the form of a dividend.

Economic indicators with impact on Johnson And Johnson's sales, demand side and costs, supply side - CSIMarket

Competition is fierce, certainly, with private label adoption one obvious concern. (In pain relief, for instance, the total global market share of private label competitors is more than 1.5x that ...

Value. Procter & Gamble beats JNJ on price-to-sales. These companies trade at a P/S of 4.2 and 3.24, respectively. PG is also ahead when it comes to price-to-book, as it has a P/B of 3.69. On the ...JnJ Competition Director: Niko Salgado. Competition Details to be release at Competition Announcement Date. EURO PARTNER PASS. Free Pass for Europe Residents with Partners BDF – Brazilian Dance Festival and Dutch Zouk Congress pass. It’s a European invasion! If you are planning to attend BDF or Dutch Zouk for 2023 please …Competition schedule is subject to change. All Adult competitors must be at Competitor Briefing 12.30pm (with the exception of Novice zouk jnj competitors who must arrive by 10.30am – this category is TBC based on sign ups.Moderna's Business Segments. Moderna operates as a single business segment focused on the discovery, development, and commercialization of mRNA medicines. The company provides a breakdown of this ...Apr 19, 2022 · April 19, 2022. New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson ’s 144,000 employees for their relentless passion ... JNJ and its competitors clearly demonstrate strong operating profits. This goes to show that even though the Pharma industry is highly competitive and revenue growth has been generally slow, the ...GlobalData’s report assesses how JNJ-8114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication ... You can make better informed decisions and gain a future-proof advantage over your competitors. Be better informed. GlobalData, the leading provider of industry intelligence, provided ...This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment ...Tools Learn Johnson & Johnson (JNJ) Alerts Watch Help Go To: Other Sectors …

JNJ's III. Quarter Q/Q Net Income Comment: Johnson and Johnson achieved in the III. Quarter 2023 above company average sequential Net Income doubling of 405.99%, to $ 26,028.00 millions, from $ 5,144.00 millions in the second quarter. Johnson And Johnson is going from strength to strength, not just claiming better then average growth, and …Johnson & Johnson (J&J) is an American multinational, pharmaceutical, and medical …Jul 21, 2023 · Johnson & Johnson's revenue growth from 2005 to 2022 is 87.95%. Johnson & Johnson has 134,500 employees, and the revenue per employee ratio is $705,895. Johnson & Johnson's peak quarterly revenue was $34.9B in 2022(q4). Johnson & Johnson peak revenue was $94.9B in 2022. Johnson & Johnson annual revenue for 2021 was 93.8B, 13.55% growth from 2020. JNJ-2113 is the only targeted oral peptide in late-stage development that is designed to selectively block the IL-23 receptor, and we believe the ICONIC studies have the potential to establish JNJ-2113 as the preferred oral treatment option for psoriasis patients," said Dinesh V. Patel, Ph.D., President and CEO of Protagonist.Instagram:https://instagram. patterson companies stockhow much is ninja traderspy stock forecastplatform for futures trading See full list on bstrategyhub.com Johnson & Johnson (JNJ 1.68%) is a well-known consumer and healthcare company that has been in operation for more than a century. Meanwhile, Intuitive Surgical ( ISRG 0.03% ) has made a name for ... car guru stockjepi ticker Competitive benchmarking is a useful tool for understanding where you can go next with your , and to see where you could be servicing your customers more effectively. It can help you see why your audience might choose a competitor over you, and work on strategies to attract them to your offering instead. is arrived a good investment May 26, 2011 · A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. You Can Confidently Add These 3 Stocks to Your Portfolio Motley Fool - Sun Nov 26, 6:15AM CST. These companies offer low-risk growth and income at a value price. SO : 70.23 (-0.37%) JNJ : 152.11 (+0.32%) WMB : 36.44 (+0.30%) Johnson & Johnson and Intuitive Surgical Might Become Ozempic's Next Victims.Moderna's Business Segments. Moderna operates as a single business segment focused on the discovery, development, and commercialization of mRNA medicines. The company provides a breakdown of this ...